Blau is the Leading Pharmaceutical Industry in Brazil
Leading Biotech Pharmaceutical Industry focused on the hospital / clinics / HMO segment with LatAm footprint
Portfolio of high complexity injectable drugs indispensable for our 7,000+ clients
High quality biological and synthetic drugs used for treatment of immunology, oncology, hematology, nephrology, infectious diseases, among others
Integrated platform, capable to produce its own biological API, develop, register, manufacture and market finished products, growing production capacity and
owned renowned brands
2
Our Growth Strategy Pillars & Operating Market
Production Chain
Capacity ExpansionVerticalization: Plasma
collection and API
Unique ability to produce the
Increased production capacity
Active Pharmaceutical Ingredient
and construction of P1000, an
(API) for biotechnological
automated complex of highly
medicines and
complex injectables in Brazil
Independence in the production
of strategic products
New Business: RD&I
M&A and
and BD
Internationalization
High complexity and relevant
Actively monitor all market for
RD&I pipeline for the
selected opportunities: strategic
institutional market.
assets or verticalization, portfolio
Potential BD partnership
expansion and geographic
through launch of innovative
presence. Blau also maintain a
products with technology
large number of products
transfer and local production
registered in the Latam Region
In Depth
Biologics
Specialties
Oncology
Others
◼ Demand is very strong
◼ Demand is higher than our
◼ High growth market worldwide
◼ Dermo cosmetics products
Understanding of
◼ Market is in shortage of selected
production capacity
◼ Strong R&D efforts
◼ Exports Sales
products
◼ Expansion of Blau São Paulo
◼ Local production and dedicated
◼ Retail Sales - condoms and drugs
Our Business Units
◼ COVID-19 impacted the supply of
◼ Acquisition of Pharma Limírio
plant with few competitors
plasma in 2020 and 2021
allowed Blau to increase capacity for
◼ Unique position to supply the market
specialty products
in 2022 onwards
3
What Are Our Competitive Advantages?
Our Differentials vs. Competitors
Examples of Leading Products & Main Competitors
1st
1st
Strong own portfolio of branded drugs
Biologic
Biologic
(Immune system)
(Anemia)
1st
Growing & pioneer biotech platform in brazil
Biologic
(Anticoagulant)
1st
Local production and large scale
Specialty
(Antibiotic)
1st
Wide Basket of drugs dedicated to hospitals and clinics
Specialty
(Muscle Relaxer)
1st
Strong RD&I capabilities
Specialty
(Antibiotic)
Source: Company, IQVIA
1st
Specialty
(Reduction of gastric acid
secretion)
1st
Oncologic
(Immune system)
1st
Specialty
(Antibiotic)
5th
Others
(Neuromuscular paralyzing
agent)
Market Position
4
P400 Plant: Our Path to Verticalization of Biotech APIs
Current
Pipeline
Verticalization
4 APIs
4 APIs
Verticalization of
GMP granted
pipeline
8 APIs
by Anvisa
Increase in
Independence in the
Potential to add sales from
Profitability
production of strategic drugs
new markets
Alfaepoetin
•
Pegfilgrastin
Good Manufacturing Practice (GMP)1
•
Filgrastin
Granted in February 2021
•
Somatotropin
Source: Company
Note:
1.
"Certificado de Boas Práticas de Fabricação e Controle (BPFC)"
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Blau Farmaceutica SA published this content on 24 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 January 2022 12:53:07 UTC.
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
BLAU FARMACÊUTICA S.A. 
